Steven Cohen's ALLO Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 221,335 shares of Allogene Therapeutics, Inc. (ALLO) worth $540,057, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in ALLO, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 679,468 shares. Largest reduction occurred in Q1 2024, reducing 679,468 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Allogene Therapeutics (ALLO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Allogene Therapeutics (ALLO) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +117,595 | Add 113.36% | 221,335 | $2.44 |
| Q4 2025 | +103,740 | New Buy | 103,740 | $1.37 |
| Q1 2024 | -679,468 | Sold Out | 0 | $0.00 |
| Q4 2023 | +679,468 | New Buy | 679,468 | $3.21 |
| Q3 2023 | -2,217 | Sold Out | 0 | $0.00 |
| Q2 2023 | +119 | Add 5.67% | 2,217 | $4.97 |
| Q1 2023 | +2,098 | New Buy | 2,098 | $4.94 |
| Q4 2022 | -293,200 | Sold Out | 0 | $0.00 |
| Q3 2022 | +293,200 | New Buy | 293,200 | $10.80 |
Steven Cohen's Allogene Therapeutics Investment FAQs
Steven Cohen first purchased Allogene Therapeutics, Inc. (ALLO) in Q3 2022, acquiring 293,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Allogene Therapeutics, Inc. (ALLO) for 9 quarters since Q3 2022.
Steven Cohen's largest addition to Allogene Therapeutics, Inc. (ALLO) was in Q4 2023, adding 679,468 shares worth $2.18 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 221,335 shares of Allogene Therapeutics, Inc. (ALLO), valued at approximately $540,057.
As of the Q1 2026 filing, Allogene Therapeutics, Inc. (ALLO) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Allogene Therapeutics, Inc. (ALLO) was 679,468 shares, as reported at the end of Q4 2023.